The FH Studies Collaboration

Familial Hypercholesterolaemia (FH) represents a major global health problem because, despite being very common, it is widely underdiagnosed, undertreated and, as a result often fatal. The consequences of FH in the form of premature atherosclerosis and cardiovascular events are potentially preventable, but require effective initiatives and policies to address the current issues and reduce the burden of disease.

To address these issues, EAS FH Studies Collaboration (FHSC) has since 2015 collected data from FH investigators from all over the world. The data is pooled, harmonised and analysed to give the investigators a better understanding of FH. EAS FHSC raises awareness of the disease and encourages the development of programmes, initiatives and policies specifically focused on FH, by joining efforts from healthcare providers, patient organizations, policy makers and the entire medical community. Read more

Latest news

  • Latest from the FHSC registry: take action now for universal cholesterol screening in early life
    Commentary to publication: Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. The Lancet; Familial hypercholesterolaemia (FH) is the most common inherited lipid disorder, affecting about one in 300 people worldwide (1). If untreated, elevated low-density lipoprotein cholesterol (LDL‑C) levels from birth confer an increased risk of premature atherosclerotic cardiovascular disease. … Read more
  • Global FHSC registry makes the case for universal cholesterol screening of children for familial hypercholesterolaemia
    December 13, 2023 – Gothenburg, Sweden Finding children with familial hypercholesterolaemia (FH), the most common inherited lipid disorder, relies on family cascade screening, usually after a parent or relative has a heart attack, as physical signs of FH in children are uncommon, meaning that detection is delayed in most. These were the key findings from … Read more
  • Consensus on Familial Hypercholesterolaemia in Children and Adolescents
    Familial Hypercholesterolaemia in children and adolescents: gaining decades of life by optimising detection and treatment Consensus Statement of the European Atherosclerosis Society Publication in full Featured Commentary Slide set Authors Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche … Read more
  • Consensus on FH
    Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease Consensus Statement of the European Atherosclerosis Society Publication in full Slide set Featured Commentary Authors Børge G. Nordestgaard*, M. John Chapman*, Steve E. Humphries, Henry N. Ginsberg, Luis Masana, Olivier S. Descamps, Olov Wiklund, Robert A. Hegele, … Read more
  • Guidelines on management of dyslipidaemia 2016
    These updated 2016 guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. The guidance includes sections on: the evaluation of laboratory lipid and apolipoprotein parameters; treatment targets; lifestyle modifications to improve the plasma lipid profile; drugs for treatment of hypercholesterolaemia and hypertriglyceridaemia; drugs affecting HDL-cholesterol; managing dyslipidaemias in different … Read more

More news